Clinical Trials Directory

Trials / Recruiting

RecruitingNCT03571763

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients

The Impact of Anti-thrombosis on Cerebral Microbleeds and Intracranial Hemorrhage in Ischemic Stroke Patients: Prospective, Multi-center, Cohort Study

Status
Recruiting
Phase
Study type
Observational
Enrollment
1,875 (estimated)
Sponsor
General Hospital of Shenyang Military Region · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this prospective cohort study is to investigate whether antithrombotic therapy in the secondary prevention of ischemic stroke increases the risk of the emerging CMBs and whether the change is associated with an increased risk of intracranial hemorrhage, providing an imaging evidence for individualized antithrombotic therapy in such patients.

Detailed description

Cerebral microbleeds(CMBs) is a subclinical lesion caused by microvascular disease in the brain, characterized by microleakage of blood. About 30% of ischemic stroke patients, 40% of the healthy people over 80 years old, and 60% of intracranial hemorrhage patients have microbleeds. With the development of imaging technology, clinically more and more patients have found microbleeds in the brain. How these patients are treated with antithrombotic drugs is not yet clear and is in urgent need of evidence. There are only a few prospective cohort studies to determine whether antithrombotic therapy increases the risk of intracranial hemorrhage in ischemic stroke patients with CMBs, but the results are uncertain. More importantly, whether antithrombotic therapy increases the incidence of the emerging CMBs, and whether the change of increased microbleeds is associated with increased intracranial hemorrhage has not been reported.

Conditions

Interventions

TypeNameDescription
OTHERSWI sequenceAcute ischemic stroke patient confirmed by SWI sequence

Timeline

Start date
2018-08-01
Primary completion
2026-12-30
Completion
2026-12-30
First posted
2018-06-28
Last updated
2025-03-18

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT03571763. Inclusion in this directory is not an endorsement.